Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee adds biosimilar definition to House Bill 117; sponsors say substitution could reduce costs
Summary
Senate Health and Human Services adopted a committee amendment to House Bill 117 inserting a statutory definition of "biosimilar" and referencing the federal standard for interchangeable biological products; sponsors said the change could permit substitution under FDA guidelines and reduce drug costs.
The Senate Health and Human Services Committee adopted a committee amendment to House Bill 117 that inserts a statutory definition of the term “biosimilar” and points to the federal standard for interchangeable biological products, committee members said.
The amendment, identified in committee as 20251611S, specifies the federal cross‑reference and adds the definition into state statute. The presenting senator said the amendment “points to the proper section of US code that……
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
